AN OVERVIEW ON PHARMACOPOEIAS IN THE WORLD AND MONOGRAPH ELABORATION TECHNIQUES by YAPAR, Evren ALGIN & ÖZDEMİRHAN, Mehmet Emre
 Review Article 
 
 
AN OVERVIEW ON PHARMACOPOEIAS IN THE WORLD AND 
MONOGRAPH ELABORATION TECHNIQUES 
 
 
ABSTRACT 
Pharmacopoeia are official sources that contain national and international rules that must be 
complied with legally and scientifically regarding substances, materials, drugs, devices and 
methods used in pharmaceutical field and pharmaceutical production.The monographs are 
consisted of general titles such as definition, production, characters, identification, tests, 
assay, storage, labelling and impurities. The World Health Organization states that sixty eight 
different pharmacopoeia continue to be used effectively in fiftysix countries around the 
world. In this review information about national and international wold pharmacopoeias, 
structure and general content of pharmacopoeias, and monograph elaboration techniques are 
given. 
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INTRODUCTION 
A pharmacopoeia, pharmacopeia, or pharmacopoea, is a scientific legal binding reference 
book, prepared by a national or regional authority, of standards and quality specifications for 
medicines used in that country or region [1]. Pharmacopoeia are official books containing 
national and international rules and methods that must be followed legally and scientifically, 
including qualitative and quantitative analysis methods of active substances and excipients 
used in pharmaceutical production. Monographsrefer to the pharmacopoeia section that 
define the definition, content, morphological (appearance), physicochemical (such as 
solubility, melting and boiling point) and biological (biological activity and the definition) 
properties, recognition-diagnostic analysis, quantification, packaging and storage conditions 
of chemical/biological/biotechnological active and auxiliary substances, herbal/animal drugs 
and preparations finished products or medicinal products.Pharmacopoeia maintains public 
health and quality of drugs by combining the procedures recommended for analysis and 
specifications for the determination of pharmaceuticals, excipients and dosage forms, usually 
consisting of general sections (tests, methods and general requirements) and special 
monographs. Pharmaceutical analysis represents a platform through which state-of-the-art 
research can affect the quality, safety and efficacy of medicines directly by pharmacopoeial 
application of scientific results into everyday practice [2]. 
 
The World Health Organization (WHO) states that sixty-eight different pharmacopoeia 
continue to be used effectively in fifty-six countries around the world and in the European 
Union, Africa Continent (African Herbal Pharmacopoeia - AfrHP and African 
Pharmacopoeia), and the WHO structure.Fifty-six countries reported to the WHO have a 
national pharmacopoeia. Pharmacopoeia of the Eurasian Economic Union (EAEU), European 
Pharmacopoeia, African Pharmacopoeia, African Herbal Pharmacopoeia are indicated as 
pharmacopoeia used regional and subregional. As an international pharmacopoeia, there is 
 The International Pharmacopoeia within the WHO [3]. A national pharmacopoeia are 
developed and published by the national pharmacopoeia authority of their 
country.Information on the name, publisher country and language of the pharmacopoeia of 
which informations are included in the WHO-index and available from various sources, are 
briefly presented below in the Table 1 [3-8]. 
 
Table 1.Extensity, name, language and publisher country some of world pharmacopoeias[3-
8]. 
Extensity  Country- Name of Pharmacopoiea - Language  
 
 
 
National 
 
Argentina – FarmacopeaArgentina – Spanish 
 
Austria – Austrian Pharmacopoeia – Russian 
 
Belarus – State Pharmacopoeia of the Republic of Belarus – Russian 
 
Brazil – Brazilian Pharmacopoeia – Portuguese/English/Spanish 
Brazil – Brazilian Homeopathic Pharmacopoeia – Portuguese/English/Spanish 
Brazil – National Formulary– Portuguese/English/Spanish 
 
Chile – FarmacopoeaChilena – Spanish 
 
China – Pharmacopoeia of the People's Republic of China – Chinese/English  
 
Croatia – Croatian Pharmacopoeia (HRF) – Croatian  
 
Czechia – PharmacopoeaBohemica – Czech  
 
Denmark – Pharmacopoea Nordica – Danish  
 
Egypt – Egyptian Pharmacopoeia – Arabic/English  
 
Estonia–PharmacaEstica – Estonian 
 
France – French Pharmacopoeia – French/English  
 
Germany – German Pharmacopoeia (DAB) –German  
Germany – German Homeopathic Pharmacopoeia (HAB) – German  
 
Greece – Greek Pharmacopoeia – Greek  
 
Hungary – PharmacopoeaHungarica – Hungarian  
 
India – Indian Pharmacopoeia – English  
 
Indonesia – Farmakope Indonesia – Indonesian  
 
Iran – Iranian Pharmacopoeia – Iranian  
 
Italy – Official Pharmacopoeia of the Italian Republic – Italian  
 
Japan – The Japanese Pharmacopoeia (JP) – Japanese/English  
 
Kazakhstan – The State Pharmacopoeia of the Republic of Kazakhstan (SPRK) – 
Kazakh/Russian 
 
Korea – The Korean Pharmacopoeia – Korean  
 
Lithuania – Lithuanian Pharmacopoeia – Lithuanian  
 
 
Mexico – Pharmacopoeia of the United Mexican States –Spanish 
Mexico – Mexican Herbal Pharmacopoeia– Spanish 
Mexico – Mexican Homeopathic Pharmacopoeia – Spanish 
Mexico – Pharmacopoeia of the United Mexican States – Spanish 
 
Pakistan – Pakistan Pharmacopoeia – English  
 
Philippines – Philippine Pharmacopeia – English  
 
Poland – FarmakopeaPolska – Polish 
 
Portugal – Farmacopeia Portuguesa – Portuguese  
 
Romanian – PharmacopeaRomână – Romania 
 
Russian Federation – State Pharmacopoeia of the Russian Federation – Russian 
 
Serbia - Serbian Pharmacopoeia - Serbian 
 
Slovakia – Codex Pharmaceutical Slovacus – Slovak  
 
Slovenia– FormulariumSlovenicum – Slovene 
 
Spain – Royal Spanish Pharmacopoeia – Spanish 
 
Switzerland – Pharmacopoea Helvetica – French/German/Italian 
 
Thailand – Thai Pharmacopoeia – English 
Thailand – Thai Herbal Pharmacopoeia – English 
 
Turkey – Turkish Pharmacopoiea (TP) – Turkish 
 
Ukraine – The State Pharmacopoeia of Ukraine – Ukrainian  
 
United Kingdom of Great Britain and Northern Ireland – British Pharmacopoeia – 
English 
 
United States of America – The United States Pharmacopeia and National 
Formulary (USP-NF) – English/Spanish 
 
Vietnam – Pharmacopoeia Vietnamica – Vietnamese/English  
 
 
Regional 
&Subregional 
 
Eurasia – Pharmacopoeia of the Eurasian Economic Union - Russian (official)  
 
European Pharmacopiea Members – European Pharmacopoeia – English/French  
 
Africa – African Pharmacopoeia – English  
Africa – African Herbal Pharmacopoeia (AfrHP) – English  
 
 
International 
 
WHO Geneva, Switzerland – The International Pharmacopoeia – English 
 
 
There are written sources containing substances and preparations in the pharmaceutical field 
since ancient civilizations in various geographies around the world.The recently published 
pharmacopoeias compatible with today's pharmacopoeia understanding are respectively; the 
Russian Pharmacopoeia has been revealed in 1778, the Polish Pharmacopoeia in 1817, the 
United States Pharmacopeia in 1820, British Pharmacopoeia in 1864, Hungarian 
 Pharmacopoeia in 1871, German Pharmacopoeia in 1872, the Japanese Pharmacopoeia in 
1886, Argentina Pharmacopoeia in 1893, the International Pharmacopoeia (WHO) in 1950, 
Chinese Pharmacopoeia in 1953, the Korean Pharmacopoeia in 1958, Indian Pharmacopoeia 
in 1960 and the European Pharmacopoeia in 1969. Many pharmacopieas have been 
developed, revised and enlarged until today [9-16]. As indicated in Table 1, most of them are 
available and national, four of them are regional/subrerional and one of them is international. 
The pharmacopoeias about which information is available are briefly indicated below. 
 
National Pharmacopoeias 
The United States Pharmacopoiea– National Formulary – USP-NF 
The first national pharmacopoeia in America was published in 1820 with the idea of creating 
a national pharmacopoeia for authorized drugs and preparations [17].USP-NF is published by 
the United States Pharmacopeia [18].USP-NF contains official substance (ingredient) and 
product monographs for official articles recognized in USP-NP. USP-NF also includes the 
monographs for compounded preparations.With some exceptions, such as the articles 
contained in the Global Health monographs, all articles that have monographs in the USP-NF 
are legally marketed or included in the articles marketed in the US. A USP-NF monograph 
for an official substance, product, or preparation may consist of various components, 
including the requirements; and a specification. General chapters provide frequently cited 
procedures, sometimes with acceptance criteria, in order to compile into one location 
repetitive information that is applicable to many monographs. USP-NF also includes Dietary 
supplements monographs, NF Admissions/Annotations, Excipients, NF monographs, General 
Test and Assays, Reagents, Reference tablets monographs [19]. 
 
The British Pharmacopoeia – BP 
The British Pharmacopoeia has been providing official standards for medicines since 1864 
[20].The Pharmacopoeial standards are designed to complement and assist the licensing and 
inspection processes and are part of the overall system for safeguarding purchasers and users 
of medicinal products in the UK. The British Pharmacopoeia is published by the British 
Pharmacopoeia Commission, Medicines and Healthcare products Regulatory Agency-
MHRA.The British Pharmacopoeia contains publicly available, legally enforceable standards 
that provide an authoritative statement of the quality that a product, material or article is 
expected to meet at any time during its period of use. It includes General Notices, 
Monographs (Medicinal and Pharmaceutical Substances, Formulated Preparations: General 
Monographs, Formulated Preparations: Specific Monographs, Herbal Drugs, Herbal Drug 
Preparations and Herbal Medicinal Products, Materials for use in the Manufacture of 
Homoeopathic Preparations, Blood-related Products, Immunological Products, 
Radiopharmaceutical Preparations, Surgical Materials), Infrared Reference Spectra chapter 
and Veterinary Volume [21]. 
 
The Japanese Pharmacopoeia – JP 
Japanese Pharmacopoeia was first published in 1886 [22].The Japanese Pharmacopoeia is 
promulgated by the Ministry of Health, Labour and Welfare-MHLW that is an official 
document that defines the specifications, criteria and standard test methods necessary to 
properly assure the quality of medicines in Japan.The Japanese Pharmacopoeia includes 
General Notices, General Rules for Crude Drugs and Preparations, General Tests, Processes 
and Apparatus (Chemical Methods, Physical Methods, Powder Property Determinations, 
Biological Tests/Biochemical Tests/Microbial Tests, Tests for Crude Drugs, Tests for 
Preparations, Tests for Containers and Packing Materials, Reference Standards; Standard 
 Solutions; Reagents, Test Solutions; Measuring Instruments, Appliances, etc.), Official 
Monographs, Crude Drugs and Related Drugs, Infrared Reference Spectra, Ultraviolet-visible 
Reference Spectra and General Information (Physics and Chemistry, Solid-state Properties, 
Biotechnological/Biological Products, Microorganisms, Crude Drugs, Drug Formulation, 
Containers and Package, Water, Reference Standards, International Harmonization) 
monographs [23]. 
 
The Turkish Pharmacopoiea- TP 
The first known Turkish national standard about materials, substances and preparations in the 
world was declared in 1502 during the time of Ottoman Empire of Sultan Beyazıt Han. The 
process that started with the publication of the first pharmacopoeia in Istanbul in 1818 has 
developed and diversified until today. The original text of the "Kanunname-iİhtisab-ı Bursa" 
in Istanbul Topkapı Museum Revan Library was prepared by Sultan II. Bayezid Han in 1502 
as edict. In this document, the quantity, weight, size and packaging characteristics and 
standards of various materials such as herbal products, textiles, food products and salt have 
been determined. The standard has been reprinted by the Turkish Standards Institution with 
the preservation of its original text and dimensions [9-12]. The first official pharmacopoeia of 
the Republic of Turkey which contains 659 monograph was published in 1930 under the 
name of “Turkish Codex”[13]. The Republic of Turkey is one of the 39 member states of the 
European Pharmacopoeia. European Pharmacopoeia used officially in Turkey but also the 
Turkish Pharmacopoeia continues its existence. The Turkish Pharmacopoeia is prepared by 
the Turkish Medicines and Medical Devices Agency-TMMDA and the official broadcast is 
“Turkish Pharmacopoeia Journal”. National monographs that are newly added, updated, 
corrected in the Turkish Pharmacopoeia are announced before this publication. Turkish 
Pharmacopoeia includes European Pharmacopoeia monographs as well as national 
monographs. It also has a section containing magistral preparation monographs in a separate 
volume. After elaborating monographs such as chemical, herbal, biological or 
biotechnological products and finished products, they are published in the Turkish 
Pharmacopoeia Journal and then in the Turkish Pharmacopoeia and become official.Since the 
7
th
version of the Turkish Pharmacopoeia published in 2017, the pharmacopoeia is being 
expanded with the increasing number of national monographs every year. In the 2019 
version, the number of national monographs has reached thirty two and most of them are 
monographs of medicinal and aromatic herbal ingredients [24]. 
 
Pharmacopoeia of the People's Republic of China - ChP 
The ministry of health published theRebublic of China‟s first pharmacopoeia as Chinese 
Pharmacopoeia in 1953. Under the umbrella of the China Food and Drug Administration-
CFDA, the Chinese Pharmacopoeia Commission-ChPC and its stakeholders (drug control 
institutions, research institutions, universities and drug manufacturers) prepare the Chinese 
Pharmacopoeia in line with the basic principles, goals and requirements of the era. The 
Chinese Pharmacopoeia contains monographs of medicinal materials and the prepared slices 
of Chinese crude drugs, vegetable, oil fat and extracts, single-item preparations, chemical 
drugs, antibiotics, biochemical drugs and radioactive drugs, pharmaceutical excipients 
andbiologicals. General Chapters includes general requirements of preparations, testing 
methods, standard substances, reagents and guidelines [25,26]. 
 
Farmacopea Argentina 
 Farmacopea Argentina is published by The National Administration of Medicines Food and 
Medical Technology-ANMAT. The 8th Edition (Vol 1,2,3,4) was released in 2011 and its 
language is Spanish [3,27]. 
 
Brazilian Pharmacopoeia 
Brazilian Pharmacopoeia is published by Pharmacopoeia Coordination Brazilian Health 
Surveillance Agency-ANVISA in three languages, Portuguese, English and Spanish. Apart 
from Brazilian Pharmacopoeia, Brazilian Homeopathic Pharmacopoeia 
(Portuguese/English/Spanish), National Formulary (Portuguese/English/Spanish), Herbal 
Medicines National Formulary (Portuguese/Spanish), Homeopathic Medicines National 
Formulary (Portuguese/English/Spanish), Herbal Medicines Memento (Portuguese) are also 
used in Brasil[3,28]. 
 
German Pharmacopoeia - DAB 
German Pharmacopoeiais published by Federal Institute for Drugs and Medical Devices-
BfArM in German. Also German Homeopathic Pharmacopoeia-HAB is used in Germany 
[3,29]. 
 
Indian Pharmacopoeia 
Indian Pharmacopoeia Farmacopea is published by Indian Pharmacopoeia Commission-IPC 
on behalf of the Ministry of Health and Family Welfare in English. Indian Pharmacopoeia 
contains procedures for analysis and specifications for the determination of quality of 
pharmaceutical substances, excipients and dosage forms. IP monograph for an official 
substance or preparation includes the article's definition, description, identification, 
packaging, storage, specifications, impurities, assay and specific tests, one or more analytical 
procedures for each test, acceptance criteria, other requirements etc. It includes General 
Chapters and Reference Data, General Notices, Dosage Forms (General Monographs), Drug 
Substances, Dosage Forms and Pharmaceutical Aids, Vaccines and Immunosera for Human 
Use, Herbs and Herbal Products, Blood and Blood-related Products, Biotechnology Products; 
Veterinary Products [30,31]. 
 
Iranian Pharmacopoeia 
Persian pharmacy history dates back to ancient times. Qarabadins were a kind of 
pharmaceutical books which was the first generation of pharmacopeias in the history, and 
these books were a registry of drugs and preparations containing dosage forms, preparation 
procedures, considerations, dose of administrations, shelf life, etc. The transition to modern 
pharmacopoeia in Iran started to be written recently, and modern medicine has replaced the 
Persian medicine, and new pharmacy education and practices have started. The first Iranian 
pharmacopoeia was published in 2004 by Iranian Ministry of Health. During lateryears, five 
other volumes of this pharmacopeia were published. The last (6
th
) volume was published in 
2015 [32,33]. 
 
Pharmacopoeia of the United Mexican States 
Pharmacopoeia of the United Mexican States is published by Permanent Commission of the 
Pharmacopoeia of the United Mexican States in Spanish. Also Mexican 
HerbalPharmacopoeia, Mexican Homeopathic Pharmacopoeia, Medical devices Supplement 
and Pharmacies Supplement is used in Mexico [3,34]. 
 
Thai Pharmacopoeia 
 Thai Pharmacopoeia is published by Thai Pharmacopoeia Committee Bureau of Drug and 
Narcotic Department of Medical Sciences on behalf of the Ministry of Public Health in 
English [3].It includes Raw material monographs, finished product monographs and infrared 
reference spectras [35]. Also Thai Homeopathic Pharmacopoeia is used in Thailand 
[3].Homeopathy treatment is a branch of alternative medicine that is the second most widely 
used system of medicine in the world and is the fastest growing. Today, homeopathy is 
preferred as a potential treatment by many people. In Thailand, although this treatment is 
quite new, homeopathy is on a rapid rise and it is becoming a booming medical business [36]. 
 
Regional and Subregional Pharmacopoeias 
The European Pharmacopoeia - EP 
The 1st Edition of European Pharmacopoeia was published as three bound volumes between 
1968 and 1976 [37].By replacing the Convention on the Elaboration of the European 
Pharmacopoeia with the Convention Protocol signed by the Governments of 38 member 
states (Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, 
Italy, Latvia, Lithuania, Luxembourg, Malta, Montenegro, Netherlands, North Macedonia, 
Norway, Poland, Portugal, Republic of Moldova, Romania, Serbia, Slovak Republic, 
Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom) and the European 
Union, the European Pharmacopoeia was prepared under the umbrella of the Council of 
Europe. The preparation of the Pharmacopoeia is the responsibility of the European 
Pharmacopoeia Commission („the Commission'), appointed in accordance with Article 5 of 
the above-mentioned Convention. It is composed of delegations appointed by the Contracting 
Parties. Each delegation consists of not more than three members chosen for their 
competence in matters within the functions of the Commission [38].The European 
Pharmacopoeia is within the body of European Directorate for the Quality of Medicines & 
HealthCare-EDQM and the official broadcast is Pharmeuropa. Monographs that are newly 
added, updated, corrected or planned to be deleted in the European Pharmacopoeia are 
announced before this publication. European Pharmacopoeia includes, General chapters 
(General notices, Methods of analysis, Materials for containers and containers, Reagents, 
General texts), General monographs, Monographs on dosage forms, Vaccines for human use 
and veterinary use, Immunosera for human use and veterinary use, Radiopharmaceutical 
preparations and starting materials for radiopharmaceutical preparations, Sutures for human 
use and veterinary use, Herbal drugs and herbal drug preparations, Homoeopathic 
preparations and monographs [3,39,40]. 
 
Pharmacopoeia of the Eurasian Economic Union  
1
st
 Edition of Pharmacopoeia of the Eurasian Economic Union is published by 
Pharmacopoeial Committee of the Eurasian Economic Union on behalf of the Eurasian 
Economic Commission in 2019. It is planned to publish the official language in Russian 
every 3 years. Participating countries in the Pharmacopoeia the Eurasian Economic Union: 
Armenia, Belarus, Kazakhstan, Kyrgyzstan and the Russian Federation [3,41]. 
 
African Pharmacopoeia 
African Pharmacopoeia is published by African Union Scientific Technical Research 
Commission-STRC in English. African Herbal Pharmacopoeia -AfrHP, another official 
source used in Africa is published by Association for African Medicinal Plants Standards in 
English [3,42]. 
 
 International Pharmacopoeia 
The International Pharmacopoeia-Ph.Int. 
The International Pharmacopoeia was born in 1874 based on the need to standardize 
terminology, determine the composition and dosage of drugs.Ph.Int. includes the 
accumulation of recommended procedures for analysis and specifications for the 
identification of pharmaceutical substances, adjuvants and dosage forms intended to serve as 
resource materials for reference or adaptation by any WHO Member State intended to build 
pharmaceutical needs [43,44].Ph.Int. compared to national and regional pharmacopoeias, it is 
published by WHO as a recommendation to help achieve a global quality specificity by 
providing international standards (including less technically claiming alternatives where 
needed) for pharmaceutical products, adjuvants and dosage forms to be accepted by Member 
States [2]. It includes General Notices, Appendices to the General Notices, Pharmaceutical 
Substances monographs, Dosage Forms (General and specific monographs), 
Radiopharmaceuticals (General monographs, Specific monographs, Methods of analysis 
(Physical and physicochemical/Chemical/Biological methods), Supplementary information), 
Methods of Analysis (Physical and physicochemical methods, Chemical methods, Biological 
methods, Methods for materials of plant origin and Pharmaceutical technical procedures), 
Infrared Reference Spectra chapter, Reagents, test solutions and volumetric solutions and 
Supplementary information [43]. 
 
Content of Pharmacopoeias  
Pharmacopoeias consist of general chapters and medicinal and pharmaceutical substances 
monographs,starting with the preface, introduction and general notices. The monographs 
whose tıtle/monograph number has changed and new, revised, corrected, deleted monograph 
information is indicated. Methods of analysis chapter describing many analytical methods to 
be applied in analysis with biological tests and assays, Materials for containers and containers 
chapter describing the materials are used for the manufacture of containers for 
pharmaceutical use, Reagents chapters containing a description of the solutions prepared for 
tests and analyzes with specified standards, Monographs on Dosage forms, Vaccines, 
Immunoseras, Blood-related Products Immunological Products, Radiopharmaceuticals, 
medical devices Herbal drugs and herbal drug preparations, Homoeopathic preparations and 
monographs, Infrared/Ultraviolet-visible Reference Spectra information of chemicals, 
Formulated Preparations and finished product monographs can be described as parts of 
pharmacopoeia [19,21,23,39]. 
 
The quality control of pharmaceutical products has a great prospect in terms of the safe 
access to treatment that patients need. The quality of the pharmaceutical products used must 
comply with relevant internationally accepted criteria. Quality in pharmaceutical products is a 
broad concept covering all aspects that affect the efficacy and safety of these products. All of 
the measures that require the assurance of pharmaceutical quality constitute the quality 
assurance system. The Quality Assurance system consists of Quality Management (QM), 
Quality Assurance (QA) and Good Manufacturing Practices (GMP) and Quality Control 
(QC). Pharmaceutical products are subjected to quality control criteria and analysis within the 
scope of internationally accepted standards and guidelines specified or guided, including 
formulation, place and form of use. Pharmacopoeias shed light on many aspects of quality 
control analyzes in pharmaceutical products [45].Basically, pharmaceutical scientists should 
be careful to select the material in accordance with the appropriate standards and specified 
quality criteria, with very careful handling of the material's use process to obtain a consistent 
pharmaceutical product [46]. 
   
 
Monograph Elaboration Tecniques 
Monographs are elaborated or revised according to certain accepted patterns. EDQM and 
WHO have published detailed documents on monograph elaboration techniques and 
procedures. The published documents are updated by intermediate and published on the 
official web pages [47]. Countries involved in monograph studies follow and implement 
these procedures.EDQM has developed detailed guides for monograph elaboration as well as 
study techniques and publishes new ones as needed. Brief information about these guides is 
given below.  
 
Style Guide of the European Pharmacopoeia has been produced to help all those involved in 
the preparation of monographs for the European Pharmacopoeia-Ph.Eur.: the groups of 
experts, secretaries of these groups, translators, national secretariats. The aim of the Style 
Guide is to provide the means of drafting clear unambiguous texts, with similar requirements 
presented in the same way in every monograph. A uniform style is of great help in conveying 
information in an easily understandable and unambiguous manner. An analyst who has 
already carried out a test prescribed in the Ph. Eur. will find it easier to set up and carry out a 
similar test presented in the same way [48]. 
 
A guide to the graphic representation and nomenclature of chemical formulae in the 
European Pharmacopoeiais the guide on nomenclature and graphic representation of 
chemical formulae has been prepared to reply to a number of questions from the European 
Pharmacopoeia Commission and users of the Ph. Eur. [49]. 
 
Technical guide for the elaboration of monographs is a guide for the authors of monographs 
and also a means of communicating the principles for the elaboration of monographs to the 
users of the European Pharmacopoeia, especially industry, licensing authorities and official 
medicines control laboratories [50]. 
 
Guide for the elaboration of monographs on vaccines and immunosera for human use is 
intended to provide guidance to authors, contributors and users of European Pharmacopoeia 
on the elaboration of monographs for vaccines and other immunological human medicinal 
products [51]. 
 
Technical Guide for the elaboration of monographs on synthetic peptides and recombinant 
DNA proteins is intended to provide guidance to authors, contributors and users of the 
European Pharmacopoeia on the elaboration of active substance monographs for synthetic 
peptides and products of recombinant DNA technology, referred to as rDNA proteins 
throughout the document [52]. 
 
General principles for monographs on finished products containing chemically defined active 
substancesis intended to provide additional information to users on how to read and apply 
future individual FP monographs. It shall be read in conjunction with the European 
Pharmacopoeia. General Notices, the relevant dosage form monograph and the general 
monograph on Pharmaceutical Preparations [53]. 
 
Guide for the elaboration of monographs on homoeopathic preparations is about stocks for 
homoeopathic preparations may be of a mineral, chemical, botanical, zoological or human 
 origin. This Guide develops the specific points which are appropriate to monographs for 
homoeopathic preparations, and which are not presented in the Technical Guide for the 
Elaboration of Monographs (referred to as the Technical Guide) and of the Ph. Eur. Style 
Guide [54]. 
 
Technical Guide for the elaboration and use of monographs on human plasma-derived 
productsis intended to provide guidance to authors, contributors and users of European 
Pharmacopoeia monographs and general chapters on medicinal products derived from human 
blood and human plasma [55]. 
 
Guide for the elaboration of monographs on radiopharmaceutical preparationsis usedfor the 
elaboration of monographs on radiopharmaceutical preparations supplements the latest 
versions of both the Style guide of the European Pharmacopoeia and the Technical Guide for 
the elaboration of monographs. In this guide, attention is given only to those subjects that are 
particular to radiopharmaceutical preparations [56]. 
 
Technical Guide for the elaboration and use of monographs for vaccines and immunological 
veterinary medicinal products is intended to provide guidance to authors, contributors and 
users of European Pharmacopoeia monographs on veterinary vaccines and other 
immunological veterinary medicinal products[57]. 
 
Technical Guide for the elaboration of monographs on fatty oils and derivatives, a guide 
which is using to achieve harmonised monographs. Accordingly, in revision of a monograph 
or in the creation of a new monograph, it should be added to the monograph if it is useful and 
suitable, taking into account the analytical parameters specified in these guidelines [58]. 
  
Technical Guide for the elaboration of monographs on herbal drugs and herbal drug 
preparationsis a guide for developing specific points unavailable in the above-mentioned 
general Guidelines regarding to herbal drug and herbal drug preparations monographs. It is 
recalled that all tests and assay methods described in a monograph must be validated 
according to the procedures stated in the Technical guide [59]. 
 
Procedure for the elaboration, revision and omission of monographs and other texts for The 
International Pharmacopoeiawas created for Ph.Int. monographs. Its main purpose is to 
ensure the quality of the drug for safe and effective use. Monographs are developed in 
accordance with the principles in the Good Pharmacopoeia Practices (GPhP), in a clear 
process and aim to harmonization and convergence of compendial quality standards to 
ultimately increase access to affordable, quality-assured medicines [60]. 
    
CONCLUSION 
In parallel with the advances in the scientific and technological fields and the developments 
in the pharmaceutical and analytical fields, the development and revisions of the 
pharmacopoeias will continue. 
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